Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

122
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
122
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

328
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
328
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

414
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
414

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The challenges in managing Psoriatic Arthritis in resource poor settings.

Best practice & research. Clinical rheumatology·2026
Same author

Worldwide trends in hyperuricaemia from 2000 to 2023: a systematic review and modelling analysis.

The Lancet. Rheumatology·2026
Same author

Assessment of vitamin E status among patients with newly diagnosed primary knee osteoarthritis in Cameroon.

Scientific reports·2026
Same author

Value of the systemic immuno-inflammatory index as a diagnostic tool for the main causes of knee pain presenting in the emergency department in Yaoundé, Cameroon.

BMC research notes·2026
Same author

Prevalence, incidence proportion and independent predictors of thromboembolic events in adults with antiphospholipid syndrome: A systematic review with meta-analysis.

Phlebology·2026
Same author

Worldwide trends in metabolic syndrome from 2000 to 2023: a systematic review and modelling analysis.

Nature communications·2025

Related Experiment Video

Updated: Jun 14, 2025

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.8K

Current Approaches to Prevent or Reverse Microbiome Dysbiosis in Chronic Inflammatory Rheumatic Diseases.

Jan René Nkeck1,2, Ange Larissa Tchuisseu-Kwangoua1,3, Adeline Pelda1,2,4

  • 1Yaoundé Rheumatology Research Team, Yaoundé, Cameroon.

Mediterranean Journal of Rheumatology
|August 30, 2024
PubMed
Summary

Microbiome dysbiosis impacts chronic inflammatory rheumatic diseases (CIRD). This review covers strategies to manage gut health for better CIRD treatment and patient outcomes.

Keywords:
chronic inflammatory rheumatic diseasesdysbiosismicrobiomepreventionsub-Saharan Africatreatment

More Related Videos

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.4K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

812

Related Experiment Videos

Last Updated: Jun 14, 2025

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.8K
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.4K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

812

Area of Science:

  • Immunology
  • Microbiology
  • Rheumatology

Background:

  • The gut microbiome plays a crucial role in immune system regulation.
  • Dysbiosis, an imbalance in the microbiome, is increasingly linked to the development and progression of chronic inflammatory rheumatic diseases (CIRD).
  • Understanding the microbiome-immune axis is vital for deciphering CIRD pathogenesis.

Purpose of the Study:

  • To review current strategies for preventing or reversing microbiome dysbiosis in the context of CIRD.
  • To provide practical insights for healthcare professionals managing CIRD patients.
  • To highlight the implications of microbiome alterations on disease determinism, clinical presentation, and treatment response.

Main Methods:

  • Literature review of existing research on microbiome dysbiosis and CIRD.
  • Synthesis of current knowledge on microbiome-modulating interventions.
  • Analysis of the impact of dysbiosis on CIRD pathogenesis and therapeutic outcomes.

Main Results:

  • Microbiome dysbiosis is a significant factor in CIRD development and clinical manifestations.
  • Various approaches can be employed to modulate the microbiome, potentially impacting CIRD.
  • Altering the microbiome may influence patient response to therapies.

Conclusions:

  • Targeting microbiome dysbiosis represents a promising therapeutic avenue for CIRD.
  • Evidence-based strategies for microbiome management can aid clinicians in treating CIRD patients.
  • Further research into microbiome interventions is warranted to optimize CIRD management.